Metabolism diseases results from malfunctioning or inadequate function of the body’s original metabolism. Metabolism diseases can also have a genetic origin, as they can be caused by genetic birth defects as well. Metabolic diseases from genetic defects have low incidence and prevalence rate. Metabolism involves breaking down of carbohydrates, proteins, and fats present in the consumed food, to generate energy. Furthermore, metabolism also involves excretion of nitrogen through urine, and breaking down or converting other substances and chemicals. This metabolism is carried out by certain enzymes and proteins designated for the respective role.
The global metabolism drugs market is estimated to be valued at US$ 7,685.0 million in 2022 and is expected to exhibit a CAGR of 6.3% during the forecast period (2022-2030).
Figure 1. Global Metabolism Drugs Market Share (%), by Therapy Type, 2022
The increasing product approval by regulatory authorities is expected to drive the growth of the global metabolism drugs market
The increasing product approval by regulatory authorities is expected to drive the growth of the global metabolism drugs market. For instance, on February 17, 2022, Agios Pharmaceuticals, Inc., a company in the field of cellular metabolism pioneering therapies for genetically defined diseases, announced that the U.S. Food and Drug Administration (FDA) has approved PYRUKYND (mitapivat) in the U.S. for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare, debilitating, lifelong hemolytic anemia. PYRUKYND is a first-in-class, oral PK activator and the first approved disease-modifying therapy for hemolytic anemia in adults with pyruvate kinase (PK) deficiency disease.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2021 | Market Size in 2022: | US$ 7,685.0 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 |
| Forecast Period 2022 to 2030 CAGR: | 6.3% | 2030 Value Projection: | US$ 12,524.8 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Merck & Co., Inc., Novartis AG, Amicus Therapeutics, AstraZeneca Plc, Boehringer Ingelheim, Shire Plc, Sanofi Genzyme, BioMarin Pharmaceutical, Inc., Horizon Pharma Plc, and GlaxoSmithKline Plc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2.Global Metabolism Drugs Market Share (%), by Region, 2022
Increasing research and development for developing metabolism drugs is expected to drive the market growth
Increasing research and development for development metabolism drugs is expected to drive the market growth over the forecast period. For instance, on May 15, 2020, Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, announced positive initial data from the confirmatory third cohort and longer-term data from the first two cohorts of the ongoing Phase 1/2 study of DTX401, an adeno-associated virus (AAV) based gene therapy for the treatment of glycogen storage disease type Ia (GSDIa).
Global Metabolism Drugs Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020.
The COVID-19 can affect the economy in three main ways by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with regard to the transportation of drugs from one place to another place which affected the research and development activities for metabolism drugs development.
Global Metabolism Drugs Market: Key Developments
On February 17, 2022, Maze Therapeutics, a company translating genetic insights into new precision medicines, announced the initiation of dosing in the company’s Phase 1 clinical trial of MZE001 in healthy volunteers. MZE001, an oral glycogen synthase (GYS1) inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup, is being evaluated for the potential oral treatment of patients with late-onset Pompe disease.
Global Metabolism Drugs Market: Restraint
The major factors that hinder the growth of the global metabolism drugs market include clinical hold on trials by market players. For instance, on June 26, 2022, Astellas Pharma Inc., a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the FORTIS Phase 1/2 trial following the occurrence of a serious adverse event (SAE) of peripheral sensory neuropathy in one of the trial participants. FORTIS is a clinical trial evaluating AT845, an investigational adeno-associated virus (AAV) gene replacement therapy in adults with Late-Onset Pompe Disease.
Key Players
Major players operating in the global metabolism drugs market include Merck & Co., Inc., Novartis AG, Amicus Therapeutics, AstraZeneca Plc, Boehringer Ingelheim, Shire Plc, Sanofi Genzyme, BioMarin Pharmaceutical, Inc., Horizon Pharma Plc, and GlaxoSmithKline Plc.
Metabolism functions improperly when enzymes and proteins are either not produced by the body (inherited disorders), or the produced enzymes do not function the way they are meant to. Metabolic disorders occur due to buildup of proteins, lipids, glycogen, urea, calcium stones, and toxic substances among others. Each of these molecules have certain designated metabolic pathways, and metabolic agents (enzymes, proteins) at work. Inability of these agents to carry out their tasks cause buildup of the molecules in the blood and other places. Few examples of metabolic diseases include gaucher disease, hereditary tyrosinemia, hereditary orotic aciduria, and fabry disease.
Market Dynamics
Increasing inorganic growth activities such as collaborations and agreement among market players is expected to drive the market growth over the forecast period. For instance, on December 10, 2021, Eli Lilly and Company, a pharmaceutical company and Regor Therapeutics Group, a biotechnology company announced multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders. According to this agreement, Eli Lilly will have a license to select Regor intellectual property with an option to extend the license. Lilly will be responsible for clinical development, manufacturing and commercialization worldwide, except for People's Republic of China, Macau, Hong Kong and Taiwan.
Furthermore, market players are increasingly focusing on clinical trials for development of enzyme replacement therapy. For instance, on June 16, 2020, Sanofi, a global biopharmaceutical company announced the results for investigational enzyme replacement therapy (ERT), avalglucosidase alfa that showed clinically meaningful improvement in critical manifestations (respiratory impairment and decreased mobility) of late-onset Pompe disease (LOPD), according to results from the Phase 3 trial. Avalglucosidase alfa met the primary endpoint demonstrating non-inferiority in improving respiratory function compared to alglucosidase alfa (standard of care) in patients with LOPD.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients